GW touts pos­i­tive sur­vival ben­e­fit in small brain can­cer study; Abl­ynx files for ul­tra-rare dis­ease drug OK

• GW Phar­ma is tout­ing claims that a com­bi­na­tion of tetrahy­dro­cannabi­nol (THC) and cannabid­i­ol (CBD) pro­duced pos­i­tive sur­vival ben­e­fits in a small study of 21 pa­tients with re­cur­rent glioblas­toma mul­ti­forme, a com­mon form of brain can­cer. The drug arm had an 83 per­cent one year sur­vival rate com­pared with 53 per­cent for pa­tients in the place­bo group. Draw­ing a di­rect link be­tween the drug and sur­vival in such a small group, though, is dif­fi­cult to do. The com­pa­ny is now ex­plor­ing a piv­otal study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER